54 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
14
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Broad Institute of Mit and Harvard
38
From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.
Laboratoires Fournier
34
Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships ofa,a-tetrahydropyranylglycine.
Menarini Ricerche
2
A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacers.
Institute of Mutagenesis and Differentiation
9
Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Cortech
129
Synopsis of some recent tactical application of bioisosteres in drug design.
Bristol Myers Squibb
47
Discovery of a potent and selective small molecule hGPR91 antagonist.
Advinus Therapeutics
20
Quinolinyl- and phenantridinyl-acetamides as bradykinin B1 receptor antagonists.
Gedeon Richter
28
2-Aminobenzophenones as a novel class of bradykinin B1 receptor antagonists.
Merck Research Laboratories
19
A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity.
Merck Research Laboratories
21
Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists.
Merck Research Laboratories
13
Benzodiazepines as potent and selective bradykinin B1 antagonists.
Merck Research Laboratories
6
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
University of Montpellier
56
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency.
Amgen
32
Discovery of potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists.
Amgen
12
Progress in structure based drug design for G protein-coupled receptors.
Heptares Therapeutics
38
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation.
Amgen
10
Bradykinin B1 receptor antagonists as potential therapeutic agents for pain.
Johnson & Johnson Pharmaceutical Research and Development
1
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
16
Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonists.
Amgen
16
Novel small molecule bradykinin B1 receptor antagonists. Part 3: hydroxyurea derivatives.
Jerini
16
Novel small molecule bradykinin B1 receptor antagonists. Part 2: 5-membered diaminoheterocycles.
Jerini
24
Novel small molecule bradykinin B1 receptor antagonists. Part 1: benzamides and semicarbazides.
Jerini
4
Synthesis and biological activity of new bradykinin pseudopeptide B1 receptor agonists containing alkylic spacers
TBA
51
1-Benzylbenzimidazoles: the discovery of a novel series of bradykinin B(1) receptor antagonists.
Neurogen
10
Bradykinin B1 receptor antagonists: an alpha-hydroxy amide with an improved metabolism profile.
Merck
19
Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic pain.
Amgen
16
Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists.
Amgen
2
Novel bradykinin-1 antagonists containing a (1,2,3,4-tetrahydro-isoquinolin-1-yl)acetic acid scaffold.
University of Szeged
39
Preparation and optimization of a series of 3-carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists.
Elan Pharmaceuticals
17
Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series.
Merck
35
Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
Amgen
16
Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.
Amgen
25
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.
Merck Research Laboratories
43
5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists.
Merck Research Laboratories
11
Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.
TBA
28
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.
Amgen
16
2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists.
Merck Research Laboratories
8
Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies.
Merck Research Laboratories
11
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.
TBA
2
A rational approach to the design and synthesis of a new bradykinin B(1) receptor antagonist.
University of Montpellier
10
Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.
University of Montpellier
147
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
Idorsia Pharmaceuticals
9
Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor.
Neurogenetic
37
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
Kochi Medical School